Viral hepatitis in China and India
It has been three years since the advent of highly effective direct acting antiviral drugs that can cure hepatitis C in >90% of the cases. There has also been tremendous progress in understanding and combating this infection including through major policy developments. The most notable achievement during this time has been the two WHO resolutions on viral hepatitis and a forthcoming Global Health Sector Strategy on Viral Hepatitis. This commissioned supplement includes an array of articles on various aspects of hepatitis B and C prevention, treatment and care in China and India.
Publication charges for this collection were funded by the Bristol-Meyer Squibb Foundation. Articles have undergone the journal's standard peer-review process overseen by the Editor-in-Chief, Jeffrey V Lazarus, who declares no competing interests. Both Prof. Lazarus and Guest Editor Kelly Safreed-Harmon were responsible for setting the scope of the series, for identifying suitable authors and encouraging appropriate submissions. Kelly Safreed-Harmon was not involved in the peer-process and declares support from Bristol-Meyer Squibb Foundation.